|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4469863A
(en)
|
1980-11-12 |
1984-09-04 |
Ts O Paul O P |
Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
|
|
US4554101A
(en)
|
1981-01-09 |
1985-11-19 |
New York Blood Center, Inc. |
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4476301A
(en)
|
1982-04-29 |
1984-10-09 |
Centre National De La Recherche Scientifique |
Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
|
|
JPS5927900A
(ja)
|
1982-08-09 |
1984-02-14 |
Wakunaga Seiyaku Kk |
固定化オリゴヌクレオチド
|
|
US4501729A
(en)
|
1982-12-13 |
1985-02-26 |
Research Corporation |
Aerosolized amiloride treatment of retained pulmonary secretions
|
|
FR2540122B1
(fr)
|
1983-01-27 |
1985-11-29 |
Centre Nat Rech Scient |
Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
|
|
US4605735A
(en)
|
1983-02-14 |
1986-08-12 |
Wakunaga Seiyaku Kabushiki Kaisha |
Oligonucleotide derivatives
|
|
US4948882A
(en)
|
1983-02-22 |
1990-08-14 |
Syngene, Inc. |
Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
|
|
US4824941A
(en)
|
1983-03-10 |
1989-04-25 |
Julian Gordon |
Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
|
|
US4587044A
(en)
|
1983-09-01 |
1986-05-06 |
The Johns Hopkins University |
Linkage of proteins to nucleic acids
|
|
US5118802A
(en)
|
1983-12-20 |
1992-06-02 |
California Institute Of Technology |
DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
|
|
US5550111A
(en)
|
1984-07-11 |
1996-08-27 |
Temple University-Of The Commonwealth System Of Higher Education |
Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
|
|
US5258506A
(en)
|
1984-10-16 |
1993-11-02 |
Chiron Corporation |
Photolabile reagents for incorporation into oligonucleotide chains
|
|
US5430136A
(en)
|
1984-10-16 |
1995-07-04 |
Chiron Corporation |
Oligonucleotides having selectably cleavable and/or abasic sites
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
US4828979A
(en)
|
1984-11-08 |
1989-05-09 |
Life Technologies, Inc. |
Nucleotide analogs for nucleic acid labeling and detection
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
US5235033A
(en)
|
1985-03-15 |
1993-08-10 |
Anti-Gene Development Group |
Alpha-morpholino ribonucleoside derivatives and polymers thereof
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5405938A
(en)
|
1989-12-20 |
1995-04-11 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US4762779A
(en)
|
1985-06-13 |
1988-08-09 |
Amgen Inc. |
Compositions and methods for functionalizing nucleic acids
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
US5317098A
(en)
|
1986-03-17 |
1994-05-31 |
Hiroaki Shizuya |
Non-radioisotope tagging of fragments
|
|
JPS638396A
(ja)
|
1986-06-30 |
1988-01-14 |
Wakunaga Pharmaceut Co Ltd |
ポリ標識化オリゴヌクレオチド誘導体
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
EP0366685B1
(en)
|
1987-06-24 |
1994-10-19 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
US5585481A
(en)
|
1987-09-21 |
1996-12-17 |
Gen-Probe Incorporated |
Linking reagents for nucleotide probes
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
US5525465A
(en)
|
1987-10-28 |
1996-06-11 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Oligonucleotide-polyamide conjugates and methods of production and applications of the same
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
JP3019994B2
(ja)
|
1987-11-30 |
2000-03-15 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
|
|
US5403711A
(en)
|
1987-11-30 |
1995-04-04 |
University Of Iowa Research Foundation |
Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
|
|
US5082830A
(en)
|
1988-02-26 |
1992-01-21 |
Enzo Biochem, Inc. |
End labeled nucleotide probe
|
|
EP0406309A4
(en)
|
1988-03-25 |
1992-08-19 |
The University Of Virginia Alumni Patents Foundation |
Oligonucleotide n-alkylphosphoramidates
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5109124A
(en)
|
1988-06-01 |
1992-04-28 |
Biogen, Inc. |
Nucleic acid probe linked to a label having a terminal cysteine
|
|
US5216141A
(en)
|
1988-06-06 |
1993-06-01 |
Benner Steven A |
Oligonucleotide analogs containing sulfur linkages
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5262536A
(en)
|
1988-09-15 |
1993-11-16 |
E. I. Du Pont De Nemours And Company |
Reagents for the preparation of 5'-tagged oligonucleotides
|
|
US5512439A
(en)
|
1988-11-21 |
1996-04-30 |
Dynal As |
Oligonucleotide-linked magnetic particles and uses thereof
|
|
US5457183A
(en)
|
1989-03-06 |
1995-10-10 |
Board Of Regents, The University Of Texas System |
Hydroxylated texaphyrins
|
|
US5599923A
(en)
|
1989-03-06 |
1997-02-04 |
Board Of Regents, University Of Tx |
Texaphyrin metal complexes having improved functionalization
|
|
US5391723A
(en)
|
1989-05-31 |
1995-02-21 |
Neorx Corporation |
Oligonucleotide conjugates
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
|
US5451463A
(en)
|
1989-08-28 |
1995-09-19 |
Clontech Laboratories, Inc. |
Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5254469A
(en)
|
1989-09-12 |
1993-10-19 |
Eastman Kodak Company |
Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
|
|
US5399676A
(en)
|
1989-10-23 |
1995-03-21 |
Gilead Sciences |
Oligonucleotides with inverted polarity
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
US5292873A
(en)
|
1989-11-29 |
1994-03-08 |
The Research Foundation Of State University Of New York |
Nucleic acids labeled with naphthoquinone probe
|
|
US5177198A
(en)
|
1989-11-30 |
1993-01-05 |
University Of N.C. At Chapel Hill |
Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
|
US5587361A
(en)
|
1991-10-15 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US5623065A
(en)
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
|
US5220007A
(en)
|
1990-02-15 |
1993-06-15 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of RNA and production of encoded polypeptides
|
|
US5214136A
(en)
|
1990-02-20 |
1993-05-25 |
Gilead Sciences, Inc. |
Anthraquinone-derivatives oligonucleotides
|
|
WO1991013080A1
(en)
|
1990-02-20 |
1991-09-05 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
|
US5321131A
(en)
|
1990-03-08 |
1994-06-14 |
Hybridon, Inc. |
Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
EP0455905B1
(en)
|
1990-05-11 |
1998-06-17 |
Microprobe Corporation |
Dipsticks for nucleic acid hybridization assays and methods for covalently immobilizing oligonucleotides
|
|
GB9011454D0
(en)
|
1990-05-22 |
1990-07-11 |
Medical Res Council |
Polynucleotide amplification
|
|
EP0536215A4
(en)
|
1990-06-29 |
1993-07-21 |
The Regents Of The University Of Michigan |
Neurofibromatosis gene
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5608046A
(en)
|
1990-07-27 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Conjugated 4'-desmethyl nucleoside analog compounds
|
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5618704A
(en)
|
1990-07-27 |
1997-04-08 |
Isis Pharmacueticals, Inc. |
Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
|
|
US5677437A
(en)
|
1990-07-27 |
1997-10-14 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5610289A
(en)
|
1990-07-27 |
1997-03-11 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogues
|
|
JPH0874B2
(ja)
|
1990-07-27 |
1996-01-10 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
遺伝子発現を検出および変調するヌクレアーゼ耐性、ピリミジン修飾オリゴヌクレオチド
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5541307A
(en)
|
1990-07-27 |
1996-07-30 |
Isis Pharmaceuticals, Inc. |
Backbone modified oligonucleotide analogs and solid phase synthesis thereof
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5218105A
(en)
|
1990-07-27 |
1993-06-08 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
|
US5688941A
(en)
|
1990-07-27 |
1997-11-18 |
Isis Pharmaceuticals, Inc. |
Methods of making conjugated 4' desmethyl nucleoside analog compounds
|
|
JPH06502300A
(ja)
|
1990-08-03 |
1994-03-17 |
サノフィ |
遺伝子発現の抑制のための化合物及び方法
|
|
US5245022A
(en)
|
1990-08-03 |
1993-09-14 |
Sterling Drug, Inc. |
Exonuclease resistant terminally substituted oligonucleotides
|
|
US5177196A
(en)
|
1990-08-16 |
1993-01-05 |
Microprobe Corporation |
Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
US5214134A
(en)
|
1990-09-12 |
1993-05-25 |
Sterling Winthrop Inc. |
Process of linking nucleosides with a siloxane bridge
|
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
|
WO1992005186A1
(en)
|
1990-09-20 |
1992-04-02 |
Gilead Sciences |
Modified internucleoside linkages
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
DE69132510T2
(de)
|
1990-11-08 |
2001-05-03 |
Hybridon, Inc. |
Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden
|
|
US5510473A
(en)
|
1990-11-09 |
1996-04-23 |
The United States Of American As Represented By The Secretary Of Health And Human Services |
Cloning of the recA gene from thermus aquaticus YT-1
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
US5371241A
(en)
|
1991-07-19 |
1994-12-06 |
Pharmacia P-L Biochemicals Inc. |
Fluorescein labelled phosphoramidites
|
|
US5571799A
(en)
|
1991-08-12 |
1996-11-05 |
Basco, Ltd. |
(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
|
|
JP2823959B2
(ja)
|
1991-10-24 |
1998-11-11 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
US5700922A
(en)
|
1991-12-24 |
1997-12-23 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
|
US5565552A
(en)
|
1992-01-21 |
1996-10-15 |
Pharmacyclics, Inc. |
Method of expanded porphyrin-oligonucleotide conjugate synthesis
|
|
US5595726A
(en)
|
1992-01-21 |
1997-01-21 |
Pharmacyclics, Inc. |
Chromophore probe for detection of nucleic acid
|
|
GB9206016D0
(en)
|
1992-03-19 |
1992-04-29 |
Sandoz Ltd |
Improvements in or relating to organic compounds
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
US5434257A
(en)
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
|
EP0646178A1
(en)
|
1992-06-04 |
1995-04-05 |
The Regents Of The University Of California |
expression cassette with regularoty regions functional in the mammmlian host
|
|
US5272250A
(en)
|
1992-07-10 |
1993-12-21 |
Spielvogel Bernard F |
Boronated phosphoramidate compounds
|
|
US5652355A
(en)
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
|
US5478745A
(en)
|
1992-12-04 |
1995-12-26 |
University Of Pittsburgh |
Recombinant viral vector system
|
|
US5574142A
(en)
|
1992-12-15 |
1996-11-12 |
Microprobe Corporation |
Peptide linkers for improved oligonucleotide delivery
|
|
US5593972A
(en)
|
1993-01-26 |
1997-01-14 |
The Wistar Institute |
Genetic immunization
|
|
ES2249760T3
(es)
|
1993-01-26 |
2006-04-01 |
The Trustees Of The University Of Pennsylvania (A Corporation Of Pennsylvania) |
Composiciones y procedimientos de administracion de materias geneticas.
|
|
US5476925A
(en)
|
1993-02-01 |
1995-12-19 |
Northwestern University |
Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
|
|
GB9304618D0
(en)
|
1993-03-06 |
1993-04-21 |
Ciba Geigy Ag |
Chemical compounds
|
|
HU9501974D0
(en)
|
1993-03-31 |
1995-09-28 |
Sterling Winthrop Inc |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
DK0733059T3
(da)
|
1993-12-09 |
2000-10-16 |
Univ Jefferson |
Forbindelser og fremgangsmåder til site-rettede mutationer i eukaryote celler
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
US5597696A
(en)
|
1994-07-18 |
1997-01-28 |
Becton Dickinson And Company |
Covalent cyanine dye oligonucleotide conjugates
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
US5962428A
(en)
|
1995-03-30 |
1999-10-05 |
Apollon, Inc. |
Compositions and methods for delivery of genetic material
|
|
US5652356A
(en)
|
1995-08-17 |
1997-07-29 |
Hybridon, Inc. |
Inverted chimeric and hybrid oligonucleotides
|
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
GB9710807D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
CA2263784A1
(en)
|
1998-03-23 |
1999-09-23 |
Megabios Corporation |
Dual-tagged proteins and their uses
|
|
US6140081A
(en)
|
1998-10-16 |
2000-10-31 |
The Scripps Research Institute |
Zinc finger binding domains for GNN
|
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US6453242B1
(en)
|
1999-01-12 |
2002-09-17 |
Sangamo Biosciences, Inc. |
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
US6734291B2
(en)
|
1999-03-24 |
2004-05-11 |
Exiqon A/S |
Synthesis of [2.2.1]bicyclo nucleosides
|
|
ATE356824T1
(de)
|
1999-05-04 |
2007-04-15 |
Santaris Pharma As |
L-ribo-lna analoge
|
|
US20040192593A1
(en)
|
1999-07-26 |
2004-09-30 |
Baylor College Of Medicine |
Protease resistant ti-growth hormone releasing hormone
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
WO2001083783A2
(en)
|
2000-04-28 |
2001-11-08 |
Genzyme Corporation |
In vivo loading of mhc
|
|
EP1276859B1
(en)
|
2000-04-28 |
2007-02-07 |
Sangamo Biosciences Inc. |
Targeted modification of chromatin structure
|
|
US7465583B2
(en)
|
2000-06-01 |
2008-12-16 |
The University Of North Carolina At Chapel Hill |
Duplexed parvovirus vectors
|
|
JP2002060786A
(ja)
|
2000-08-23 |
2002-02-26 |
Kao Corp |
硬質表面用殺菌防汚剤
|
|
US7879540B1
(en)
|
2000-08-24 |
2011-02-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
|
US20040224385A1
(en)
|
2001-08-20 |
2004-11-11 |
Barbas Carlos F |
Zinc finger binding domains for cnn
|
|
US7060809B2
(en)
|
2001-09-04 |
2006-06-13 |
Exiqon A/S |
LNA compositions and uses thereof
|
|
AU2003219847A1
(en)
|
2002-02-21 |
2003-09-09 |
The Wistar Institute Of Anatomy And Biology |
Methods and compositions for reversibly controlling expression of target genes in cells
|
|
US7449561B1
(en)
|
2002-02-26 |
2008-11-11 |
City Of Hope |
Alterations in the dystrophin gene associated with sporadic dilated cardiomyopathy
|
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
|
EP1519714B1
(en)
|
2002-06-28 |
2010-10-20 |
Protiva Biotherapeutics Inc. |
Method and apparatus for producing liposomes
|
|
EP1573004A4
(en)
|
2002-11-04 |
2006-08-09 |
Advisys Inc |
SYNTHETIC MUSCLE PROMOTERS WITH INHERENT CELLS NATURALLY OBTAINING REGULATORY SEQUENCES EXCELLENT ACTIVITIES
|
|
AU2004263884A1
(en)
|
2003-08-08 |
2005-02-17 |
President And Fellows Of Harvard College |
SiRNA based methods for treating Alzheimer's disease
|
|
CA2539439C
(en)
|
2003-09-19 |
2012-10-23 |
Sangamo Biosciences, Inc. |
Engineered zinc finger proteins for regulation of gene expression
|
|
US20070192880A1
(en)
|
2003-10-03 |
2007-08-16 |
University Of Rochester |
Horming response element binding transregulators
|
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
|
CA2569664C
(en)
|
2004-06-07 |
2013-07-16 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
|
US7745651B2
(en)
|
2004-06-07 |
2010-06-29 |
Protiva Biotherapeutics, Inc. |
Cationic lipids and methods of use
|
|
US7728118B2
(en)
|
2004-09-17 |
2010-06-01 |
Promega Corporation |
Synthetic nucleic acid molecule compositions and methods of preparation
|
|
JP5639338B2
(ja)
|
2005-07-27 |
2014-12-10 |
プロチバ バイオセラピューティクス インコーポレイティッド |
リポソームの製造システムおよび製造方法
|
|
CN101278041A
(zh)
|
2005-08-05 |
2008-10-01 |
密执安州大学 |
来自actinobacillus succinogenes130z（atcc 55618）用于从a.succinogenes c4－途径生产化学产品的基因
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
PL2578685T3
(pl)
|
2005-08-23 |
2020-01-31 |
The Trustees Of The University Of Pennsylvania |
Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
|
|
EP2046806A4
(en)
|
2006-07-05 |
2009-10-21 |
Scripps Research Inst |
THROUGH DIRECT EVOLUTION FOR CATALYSIS OPTIMIZED, CHIMERIC ZINC FINGER RECOMBINATION
|
|
EP2097538A4
(en)
|
2006-12-07 |
2011-11-30 |
Switchgear Genomics |
TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
|
|
US8198244B2
(en)
|
2006-12-07 |
2012-06-12 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Regulation of skin characteristics by DICKKOPF1 (DKK1)
|
|
WO2008086807A2
(en)
|
2007-01-19 |
2008-07-24 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
|
US20100261175A1
(en)
|
2007-06-15 |
2010-10-14 |
Exiqon A/S |
Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
US20100076057A1
(en)
|
2008-09-23 |
2010-03-25 |
Northwestern University |
TARGET DNA INTERFERENCE WITH crRNA
|
|
AU2009303345B2
(en)
|
2008-10-09 |
2015-08-20 |
Arbutus Biopharma Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
|
EP2998402A1
(en)
|
2008-10-17 |
2016-03-23 |
Joule Unlimited Technologies, Inc. |
Ethanol production by microorganisms
|
|
EP3133160B1
(en)
|
2008-10-24 |
2018-12-12 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for dmd
|
|
WO2010075424A2
(en)
|
2008-12-22 |
2010-07-01 |
The Regents Of University Of California |
Compositions and methods for downregulating prokaryotic genes
|
|
EP2206723A1
(en)
|
2009-01-12 |
2010-07-14 |
Bonas, Ulla |
Modular DNA-binding domains
|
|
WO2010108126A2
(en)
|
2009-03-19 |
2010-09-23 |
Fate Therapeutics, Inc. |
Reprogramming compositions and methods of using the same
|
|
KR20220038506A
(ko)
|
2009-06-10 |
2022-03-28 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
|
WO2011036640A2
(en)
|
2009-09-24 |
2011-03-31 |
Cellectis |
Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
|
|
LT2494039T
(lt)
|
2009-10-31 |
2019-07-25 |
Genesis Technologies Limited |
Ląstelių perprogramavimo būdai ir jų panaudojimas
|
|
PT2816112T
(pt)
|
2009-12-10 |
2018-11-20 |
Univ Iowa State Res Found Inc |
Modificação do adn modificada pelo efector tal
|
|
US20110197290A1
(en)
|
2010-02-11 |
2011-08-11 |
Fahrenkrug Scott C |
Methods and materials for producing transgenic artiodactyls
|
|
AU2011256838B2
(en)
|
2010-05-17 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Novel DNA-binding proteins and uses thereof
|
|
IT1400425B1
(it)
|
2010-06-08 |
2013-05-31 |
Amsterdam Molecular Therapeutics Bv |
Modified snrnas for use in therapy.
|
|
EP2517731A1
(en)
|
2011-04-07 |
2012-10-31 |
Ludwig-Maximilians-Universität München |
Method of activating a target gene in a cell
|
|
EP2729567B1
(en)
|
2011-07-08 |
2016-10-05 |
Cellectis |
Method for increasing the efficiency of double-strand break-induced mutagenssis
|
|
WO2013074999A1
(en)
|
2011-11-16 |
2013-05-23 |
Sangamo Biosciences, Inc. |
Modified dna-binding proteins and uses thereof
|
|
US8450107B1
(en)
|
2011-11-30 |
2013-05-28 |
The Broad Institute Inc. |
Nucleotide-specific recognition sequences for designer TAL effectors
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
WO2013152220A2
(en)
|
2012-04-04 |
2013-10-10 |
Life Technologies Corporation |
Tal-effector assembly platform, customized services, kits and assays
|
|
EP2841572B1
(en)
|
2012-04-27 |
2019-06-19 |
Duke University |
Genetic correction of mutated genes
|
|
US9738879B2
(en)
|
2012-04-27 |
2017-08-22 |
Duke University |
Genetic correction of mutated genes
|
|
ES2728782T3
(es)
|
2012-05-25 |
2019-10-28 |
Univ California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
CN116622704A
(zh)
|
2012-07-25 |
2023-08-22 |
布罗德研究所有限公司 |
可诱导的dna结合蛋白和基因组干扰工具及其应用
|
|
US9567581B2
(en)
|
2012-08-07 |
2017-02-14 |
The General Hospital Corporation |
Selective reactivation of genes on the inactive X chromosome
|
|
EP3789405A1
(en)
|
2012-10-12 |
2021-03-10 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
EP4397759A3
(en)
|
2012-10-23 |
2024-10-09 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
CA2890110C
(en)
|
2012-11-01 |
2023-05-02 |
Factor Bioscience Inc. |
Methods and products for expressing proteins in cells
|
|
US20140140969A1
(en)
|
2012-11-20 |
2014-05-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for muscular dystrophies
|
|
DK3363902T3
(da)
|
2012-12-06 |
2020-01-02 |
Sigma Aldrich Co Llc |
Crispr-baseret genommodifikation og -regulering
|
|
WO2014093479A1
(en)
|
2012-12-11 |
2014-06-19 |
Montana State University |
Crispr (clustered regularly interspaced short palindromic repeats) rna-guided control of gene regulation
|
|
MX380562B
(es)
|
2012-12-12 |
2025-03-12 |
Broad Inst Inc |
Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
|
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
KR102955556B1
(ko)
|
2012-12-12 |
2026-04-22 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
|
|
IL308158A
(en)
|
2012-12-17 |
2023-12-01 |
Harvard College |
Rna-guided human genome engineering
|
|
WO2014145838A2
(en)
|
2013-03-15 |
2014-09-18 |
Britt Edward J |
Energy conversion device and method for making and using same
|
|
HK1220154A1
(zh)
*
|
2013-03-15 |
2017-04-28 |
Sarepta Therapeutics, Inc. |
改进的用於治疗肌营养不良的组合物
|
|
CN105408483A
(zh)
|
2013-03-15 |
2016-03-16 |
通用医疗公司 |
遗传和表观遗传调节蛋白至特定基因组基因座的rna引导的靶向
|
|
EP2997146A4
(en)
|
2013-05-15 |
2017-04-26 |
Sangamo BioSciences, Inc. |
Methods and compositions for treatment of a genetic condition
|
|
EP3603679B1
(en)
|
2013-06-04 |
2022-08-10 |
President and Fellows of Harvard College |
Rna-guided transcriptional regulation
|
|
WO2014197748A2
(en)
|
2013-06-05 |
2014-12-11 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
JP6738728B2
(ja)
|
2013-06-17 |
2020-08-19 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用
|
|
WO2014204723A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions
|
|
SG11201510327TA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
|
|
PL3019619T3
(pl)
|
2013-07-11 |
2022-01-10 |
Modernatx, Inc. |
Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania
|
|
US10421957B2
(en)
|
2013-07-29 |
2019-09-24 |
Agilent Technologies, Inc. |
DNA assembly using an RNA-programmable nickase
|
|
US20150044772A1
(en)
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
Crispr/cas system-based novel fusion protein and its applications in genome editing
|
|
TW201536329A
(zh)
|
2013-08-09 |
2015-10-01 |
Isis Pharmaceuticals Inc |
用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
|
|
US10265347B2
(en)
|
2013-08-29 |
2019-04-23 |
Norimasa Miura |
Biomolecular group related to cell anti-aging
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
WO2015048690A1
(en)
|
2013-09-27 |
2015-04-02 |
The Regents Of The University Of California |
Optimized small guide rnas and methods of use
|
|
CN111218447B
(zh)
|
2013-11-07 |
2024-10-11 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
CA2932439A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
|
CN111206032B
(zh)
|
2013-12-12 |
2024-07-19 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
KR20160097338A
(ko)
|
2013-12-12 |
2016-08-17 |
더 브로드 인스티튜트, 인코퍼레이티드 |
뉴클레오티드 반복 장애에서의 ｃｒｉｓｐｒ-ｃａｓ 시스템의 조성물 및 방법 및 용도
|
|
US10752881B2
(en)
|
2014-01-29 |
2020-08-25 |
Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Trans-differentiation of differentiation cells
|
|
US9938521B2
(en)
|
2014-03-10 |
2018-04-10 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
|
|
EP3129490A4
(en)
|
2014-04-08 |
2017-10-04 |
North Carolina State University |
Methods and compositions for rna-directed repression of transcription using crispr-associated genes
|
|
SG11201608701QA
(en)
|
2014-04-18 |
2016-11-29 |
Editas Medicine Inc |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
AU2015277369B2
(en)
|
2014-06-16 |
2021-08-19 |
The Johns Hopkins University |
Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter
|
|
EP3169776B1
(en)
|
2014-07-14 |
2025-09-03 |
The Regents of The University of California |
Crispr/cas transcriptional modulation
|
|
CA2954920A1
(en)
|
2014-07-14 |
2016-01-21 |
The Regents Of The University Of California |
A protein tagging system for in vivo single molecule imaging and control of gene transcription
|
|
WO2016022866A1
(en)
|
2014-08-07 |
2016-02-11 |
Agilent Technologies, Inc. |
Cis-blocked guide rna
|
|
US20160058889A1
(en)
|
2014-08-11 |
2016-03-03 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
MA40880A
(fr)
|
2014-10-30 |
2017-09-05 |
Temple Univ Of The Commonwealth |
Éradication guidée par l'arn du virus jc humain et d'autres polyomavirus
|
|
WO2016081924A1
(en)
|
2014-11-20 |
2016-05-26 |
Duke University |
Compositions, systems and methods for cell therapy
|
|
EP3221457B1
(en)
|
2014-11-21 |
2019-03-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide rnas
|
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
US10190106B2
(en)
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
|
US11208638B2
(en)
|
2015-01-12 |
2021-12-28 |
The Regents Of The University Of California |
Heterodimeric Cas9 and methods of use thereof
|
|
US20190388469A1
(en)
|
2015-01-30 |
2019-12-26 |
The Regents Of The University Of California |
Protein delivery in primary hematopoietic cells
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
US20160281166A1
(en)
|
2015-03-23 |
2016-09-29 |
Parabase Genomics, Inc. |
Methods and systems for screening diseases in subjects
|
|
CA2981508A1
(en)
|
2015-04-01 |
2016-10-06 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
|
|
EP3286318A2
(en)
|
2015-04-22 |
2018-02-28 |
Mina Therapeutics Limited |
Sarna compositions and methods of use
|
|
EP4019975A1
(en)
|
2015-04-24 |
2022-06-29 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
|
WO2016187717A1
(en)
|
2015-05-26 |
2016-12-01 |
Exerkine Corporation |
Exosomes useful for genome editing
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
EP3929287A3
(en)
|
2015-06-18 |
2022-04-13 |
The Broad Institute, Inc. |
Crispr enzyme mutations reducing off-target effects
|
|
JP6862415B2
(ja)
|
2015-07-24 |
2021-04-21 |
ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ |
植物病原性菌類の駆除に有用なピリジン化合物
|
|
WO2017069829A2
(en)
|
2015-07-31 |
2017-04-27 |
The Trustees Of Columbia University In The City Of New York |
High-throughput strategy for dissecting mammalian genetic interactions
|
|
KR20240132120A
(ko)
|
2015-08-25 |
2024-09-02 |
듀크 유니버시티 |
Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법
|
|
US11091780B2
(en)
|
2015-09-18 |
2021-08-17 |
The Regents Of The University Of California |
Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
|
|
EP3332008A4
(en)
|
2015-09-23 |
2019-01-16 |
Université Laval |
CHANGE OF THE DYSTROPHINE GENE AND USES THEREOF
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
WO2017070632A2
(en)
|
2015-10-23 |
2017-04-27 |
President And Fellows Of Harvard College |
Nucleobase editors and uses thereof
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
EP4279084B1
(en)
|
2015-10-28 |
2025-06-11 |
Vertex Pharmaceuticals Inc. |
Materials and methods for treatment of duchenne muscular dystrophy
|
|
US11566052B2
(en)
|
2015-11-11 |
2023-01-31 |
Lonza Ltd. |
CRISPR-associated (Cas) proteins with reduced immunogenicity
|
|
US11306308B2
(en)
|
2015-11-13 |
2022-04-19 |
Massachusetts Institute Of Technology |
High-throughput CRISPR-based library screening
|
|
US12214054B2
(en)
*
|
2015-11-30 |
2025-02-04 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
WO2017123559A2
(en)
|
2016-01-11 |
2017-07-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric proteins and methods of regulating gene expression
|
|
EP3199632A1
(en)
|
2016-01-26 |
2017-08-02 |
ACIB GmbH |
Temperature-inducible crispr/cas system
|
|
JP6998313B2
(ja)
|
2016-02-11 |
2022-02-04 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
細胞のゲノムにおける変異ジストロフィン遺伝子を修飾する方法及び組成物
|
|
WO2017165859A1
(en)
|
2016-03-24 |
2017-09-28 |
Research Institute At Nationwide Children's Hospital |
Modified viral capsid proteins
|
|
EP3443081A4
(en)
|
2016-04-13 |
2019-10-30 |
Duke University |
CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
|
|
CN109121395B
(zh)
|
2016-04-15 |
2022-08-09 |
全国儿童医院研究所 |
腺相关病毒载体递送β-肌聚糖和微RNA-29以及肌营养不良症的治疗
|
|
CN109661470A
(zh)
|
2016-04-15 |
2019-04-19 |
宾夕法尼亚州大学信托人 |
新型aav8突变衣壳和含有其的组合物
|
|
WO2017193029A2
(en)
|
2016-05-05 |
2017-11-09 |
Duke University |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy
|
|
WO2017201199A1
(en)
|
2016-05-17 |
2017-11-23 |
Duke University |
Compositions and methods for the treatment of prader-willi syndrome
|
|
US20170362635A1
(en)
|
2016-06-20 |
2017-12-21 |
University Of Washington |
Muscle-specific crispr/cas9 editing of genes
|
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
|
KR20190024977A
(ko)
|
2016-06-30 |
2019-03-08 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머
|
|
CA3030587A1
(en)
|
2016-07-15 |
2018-01-18 |
Salk Institute For Biological Studies |
Methods and compositions for genome editing in non-dividing cells
|
|
CA3031071A1
(en)
|
2016-07-18 |
2018-01-25 |
Jaan Biotherapeutics, Llc |
Compositions and methods for treatment of cardiac diseases
|
|
WO2018017751A1
(en)
|
2016-07-19 |
2018-01-25 |
Supereye, Inc. |
Systems and methods for predictive visual rendering
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Ｃｐｆ１に基づくゲノム編集の治療適用
|
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
|
US11352647B2
(en)
|
2016-08-17 |
2022-06-07 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
MX2019002004A
(es)
|
2016-08-19 |
2019-10-09 |
Whitehead Inst Biomedical Res |
Metodos para editar la metilacion del adn.
|
|
JP7050215B2
(ja)
|
2016-08-19 |
2022-04-08 |
ツールゲン インコーポレイテッド |
人工的に操作された血管新生調節系
|
|
EP3500677A4
(en)
|
2016-08-20 |
2020-04-01 |
Avellino Lab USA, Inc. |
SINGLE GUIDE RNA, CRISPR / CAS9 SYSTEMS AND METHOD FOR USE THEREOF
|
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
EP3532616A1
(en)
|
2016-10-28 |
2019-09-04 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus
|
|
AU2017364106A1
(en)
|
2016-11-28 |
2019-06-20 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by CRISPR/Cpfl-mediated gene editing
|
|
US20200056206A1
(en)
|
2016-12-01 |
2020-02-20 |
UNIVERSITé LAVAL |
Crispr-based treatment of friedreich ataxia
|
|
CA3046220A1
(en)
|
2016-12-08 |
2018-06-14 |
The Board Of Regents Of The University Of Texas System |
Dmd reporter models containing humanized duschene muscular dystrophy mutations
|
|
JOP20190166A1
(ar)
|
2017-01-05 |
2019-07-02 |
Univ Texas |
استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي
|
|
US11136555B2
(en)
|
2017-03-01 |
2021-10-05 |
Elixirgen Scientific, Inc. |
Compositions and methods for differentiation of human pluripotent stem cells into desired cell types
|
|
WO2018160908A1
(en)
|
2017-03-03 |
2018-09-07 |
Flagship Pioneering, Inc. |
Methods and systems for modifying dna
|
|
US10687520B2
(en)
|
2017-03-07 |
2020-06-23 |
The Board Of Regents Of The University Of Texas System |
Generation and correction of a humanized mouse model with a deletion of dystrophin exon 44
|
|
US20200010519A1
(en)
|
2017-03-10 |
2020-01-09 |
Institut National De La Sante Et De La Recherche Medicale(Inserm) |
Nuclease fusions for enhancing genome editing by homology-directed transgene integration
|
|
EP3600428A4
(en)
|
2017-03-23 |
2020-08-26 |
Dnarx |
SYSTEMS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS IN VIVO
|
|
CN110892069B
(zh)
|
2017-03-30 |
2024-02-09 |
国立大学法人京都大学 |
基于基因组编辑的外显子跳跃诱导方法
|
|
AU2018251801B2
(en)
|
2017-04-12 |
2024-11-07 |
Massachusetts Institute Of Technology |
Novel type VI CRISPR orthologs and systems
|
|
US20180305719A1
(en)
|
2017-04-19 |
2018-10-25 |
The Board Of Trustees Of The University Of Illinois |
Vectors For Integration Of DNA Into Genomes And Methods For Altering Gene Expression And Interrogating Gene Function
|
|
WO2018208998A1
(en)
|
2017-05-10 |
2018-11-15 |
The Regents Of The University Of California |
Directed editing of cellular rna via nuclear delivery of crispr/cas9
|
|
EP3420811A1
(en)
|
2017-06-29 |
2019-01-02 |
Paris Sciences et Lettres - Quartier Latin |
Non-human model for neurofibromatosis type 1
|
|
US11441135B2
(en)
|
2017-07-07 |
2022-09-13 |
Toolgen Incorporated |
Target-specific CRISPR mutant
|
|
US11279765B2
(en)
|
2017-07-08 |
2022-03-22 |
The General Hospital Corporation |
Compositions and methods to improve anti-angiogenic therapy and immunotherapy
|
|
EP3712272A4
(en)
|
2017-07-25 |
2021-10-13 |
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences |
METHOD FOR MODULATION OF RNA SPLICE BY INDUCTION OF A BASE MUTATION AT THE SPLICE POINT OR A BASE SUBSTITUTION IN THE POLYPYRIMIDINE REGION
|
|
WO2019023291A2
(en)
|
2017-07-25 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR PRODUCTION AND DECODING OF GUIDE RNA LIBRARIES AND USES THEREOF
|
|
EP3441461A1
(en)
|
2017-08-11 |
2019-02-13 |
Baylor College of Medicine |
Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy
|
|
EP3668983A1
(en)
|
2017-08-18 |
2020-06-24 |
The Board of Regents of The University of Texas System |
Exon deletion correction of duchenne muscular dystrophy mutations in the dystrophin actin binding domain 1 using crispr genome editing
|
|
US20230038956A1
(en)
|
2017-08-31 |
2023-02-09 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
EP3687548A4
(en)
|
2017-09-29 |
2021-05-26 |
The Regents of the University of California |
MULTI-ARMED POLYROTAXANE PLATFORM FOR PROTECTED NUCLEIC ACID DELIVERY
|
|
WO2019079514A1
(en)
|
2017-10-17 |
2019-04-25 |
Massachusetts Institute Of Technology |
METHODS OF FUNCTIONAL DISSECTION AT THE GENOME SCALE AT HIGH RESOLUTION OF TRANSCRIPTIONAL REGULATORY REGIONS
|
|
BR112020004351A2
(pt)
|
2017-10-19 |
2020-09-08 |
Curevac Ag |
moléculas de ácido nucleico artificial
|
|
LT3700570T
(lt)
|
2017-10-23 |
2025-04-10 |
Stoke Therapeutics, Inc. |
Priešprasmiai oligomerai, skirti būklių ir ligų, pagrįstų nonsens kodono nulemta mrnr degradacija, gydymui
|
|
MA50579A
(fr)
|
2017-11-09 |
2020-09-16 |
Crispr Therapeutics Ag |
Systèmes crispr/cas ou crispr/cpf1 à auto-inactivation (sin) et leurs utilisations
|
|
EP3720508A4
(en)
|
2017-12-08 |
2021-09-01 |
University of Connecticut |
COMPOSITIONS AND METHODS FOR TREATMENT OF GENOMIC FOOTPRINT DISORDERS
|
|
EP3723774A4
(en)
|
2017-12-15 |
2021-09-08 |
The Board of Trustees of the Leland Stanford Junior University |
COMPOSITIONS AND METHODS OF INHIBITION OF T-CELL EXHAUSTATION
|
|
US11293019B2
(en)
|
2017-12-22 |
2022-04-05 |
Gflas Life Sciences, Inc. |
Chimeric genome engineering molecules and methods
|
|
CA3086885A1
(en)
|
2017-12-28 |
2019-07-04 |
Kyoto University |
Composition for modifying target gene
|
|
EP3735462A1
(en)
|
2018-01-05 |
2020-11-11 |
The Board of Regents of The University of Texas System |
Therapeutic crispr/cas9 compositions and methods of use
|
|
KR20200124702A
(ko)
|
2018-02-23 |
2020-11-03 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
신규한 cas9 오르소로그
|
|
US20210254049A1
(en)
|
2018-04-20 |
2021-08-19 |
Cellino Biotech, Inc. |
Directed cell fate specification and targeted maturation
|
|
WO2019213626A1
(en)
|
2018-05-03 |
2019-11-07 |
President And Fellows Of Harvard College |
In vivo homology directed repair in heart, skeletal muscle, and muscle stem cells
|
|
EP3802802A4
(en)
|
2018-05-30 |
2023-04-19 |
Tune Therapeutics, Inc. |
CELLULAR THERAPY
|
|
WO2020018918A1
(en)
|
2018-07-19 |
2020-01-23 |
The Board Of Trustees Of The University Of Illinois |
Methods for exon skipping and gene knockout using base editors
|
|
EP3897748A4
(en)
|
2018-12-20 |
2023-01-25 |
Ohio State Innovation Foundation |
COMPOSITIONS AND METHODS FOR REPROGRAMMING DISEASE MUSCLE SKELETAL CELLS
|
|
BR102019009665A2
(pt)
|
2018-12-21 |
2022-02-08 |
Jacques P. Tremblay |
Modificação da proteína precursora beta amiloide (app) através da edição de base usando o sistema crispr/cas9
|
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
|
CN114096666B
(zh)
|
2019-02-13 |
2025-03-18 |
比姆医疗股份有限公司 |
治疗血红素病变的组合物和方法
|
|
JP7881154B2
(ja)
|
2019-04-12 |
2026-06-29 |
デューク ユニバーシティ |
ジストロフィン機能を修復するためのＣＲＩＳＰＲ／Ｃａｓをベースにした塩基編集組成物
|
|
TW202100748A
(zh)
|
2019-04-14 |
2021-01-01 |
美國公爵大學 |
恢復肌縮蛋白功能之基於ｃｒｉｓｐｒ／ｃａｓ之基因組編輯組合物
|
|
TWI887234B
(zh)
|
2019-04-14 |
2025-06-21 |
美國公爵大學 |
治療杜興氏（ｄｕｃｈｅｎｎｅ）肌肉失養症之大型突變熱點之ａａｖ載體介導之刪除
|
|
WO2020257671A1
(en)
|
2019-06-20 |
2020-12-24 |
Celgene Corporation |
Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
|
|
US20220396790A1
(en)
|
2019-08-08 |
2022-12-15 |
Duke University |
High-throughput screening platform for engineering next-generation gene therapy vectors
|
|
CA3151816A1
(en)
|
2019-08-19 |
2021-02-25 |
Duke University |
Skeletal myoblast progenitor cell lineage specification by crispr/cas9-based transcriptional activators
|
|
CA3151336A1
(en)
|
2019-08-19 |
2021-02-25 |
Duke University |
Compositions and methods for identifying regulators of cell type fate specification
|
|
WO2021055956A1
(en)
|
2019-09-20 |
2021-03-25 |
The Uab Research Foundation |
Methods of treatment of neurofibromatosis type 1 (nf1) and nf1-mediated conditions and compositions for use in such methods
|
|
EP4038204A4
(en)
|
2019-10-02 |
2023-09-13 |
Duke University |
EPIGENETIC MODULATION OF GENOMIC TARGETS TO REGULATE THE EXPRESSION OF GENES ASSOCIATED WITH PWS
|
|
EP4069314A4
(en)
|
2019-12-03 |
2024-06-26 |
Duke University |
SYSTEMS AND METHODS FOR LIPID NANOPARTICLE DELIVERY OF GENE EDITING MACHINERY
|
|
US20230201375A1
(en)
|
2020-04-27 |
2023-06-29 |
Duke University |
Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1)
|
|
EP4125349A4
(en)
|
2020-04-27 |
2024-07-10 |
Duke University |
GENE EDITING OF SATELLITE CELLS IN VIVO USING AAV VECTORS ENCODING MUSCLE-SPECIFIC PROMOTERS
|
|
WO2021222327A1
(en)
|
2020-04-27 |
2021-11-04 |
Duke University |
A high-throughput screening method to discover optimal grna pairs for crispr-mediated exon deletion
|
|
US20230303975A1
(en)
|
2020-08-21 |
2023-09-28 |
Julius-Maximilians-Universität Würzburg |
Modified lymphocytes
|
|
WO2022076901A1
(en)
|
2020-10-09 |
2022-04-14 |
Duke University |
Novel targets for reactivation of prader-willi syndrome-associated genes
|
|
WO2022081612A1
(en)
|
2020-10-12 |
2022-04-21 |
Duke University |
Crispr/cas-based base editing composition for restoring dystrophin function
|
|
WO2022087321A1
(en)
|
2020-10-21 |
2022-04-28 |
Duke University |
Dual aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy
|
|
WO2022103935A1
(en)
|
2020-11-11 |
2022-05-19 |
The Trustees Of Columbia University In The City Of New York |
Multiplex epigenome editing
|
|
EP4244345A4
(en)
|
2020-11-13 |
2024-10-16 |
Duke University |
TARGETED GENE REGULATION OF HUMAN IMMUNE CELLS USING CRISPR-CAS SYSTEMS
|
|
WO2022133062A1
(en)
|
2020-12-16 |
2022-06-23 |
Epicrispr Biotechnologies, Inc. |
Systems and methods for engineering characteristics of a cell
|
|
WO2022187288A2
(en)
|
2021-03-01 |
2022-09-09 |
Duke University |
Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
|
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
EP4463549A2
(en)
|
2022-01-14 |
2024-11-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
US20240058425A1
(en)
|
2022-03-08 |
2024-02-22 |
Duke University |
Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
|
|
EP4508096A4
(en)
|
2022-04-13 |
2026-07-08 |
Univ Duke |
EFFECTOR DOMAINS FOR CRISPR-CAS SYSTEMS
|
|
CA3260237A1
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression
|
|
EP4554967A2
(en)
|
2022-07-12 |
2025-05-21 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
US20260053950A1
(en)
|
2022-08-18 |
2026-02-26 |
Duke University |
Epigenetic modulation of genomic targets to control expression of pws-associated genes
|
|
WO2024040254A2
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
|
JP2025531268A
(ja)
|
2022-09-19 |
2025-09-19 |
チューン セラピューティクス インコーポレイテッド |
Ｔ細胞機能を調節するための組成物、システム、および方法
|
|
WO2024081937A2
(en)
|
2022-10-13 |
2024-04-18 |
Duke University |
Cas12a fusion proteins and methods of using same
|